1,841,172 Shares in MacroGenics, Inc. $MGNX Purchased by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. purchased a new position in shares of MacroGenics, Inc. (NASDAQ:MGNX) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,841,172 shares of the biopharmaceutical company’s stock, valued at approximately $2,964,000. Jefferies Financial Group Inc. owned about 2.91% of MacroGenics at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MGNX. R Squared Ltd acquired a new position in MacroGenics during the fourth quarter worth about $26,000. Engineers Gate Manager LP acquired a new position in MacroGenics during the second quarter worth about $28,000. SG Americas Securities LLC boosted its position in MacroGenics by 55.9% during the third quarter. SG Americas Securities LLC now owns 17,179 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 6,161 shares during the last quarter. Walleye Capital LLC purchased a new position in MacroGenics during the second quarter worth about $30,000. Finally, Cresset Asset Management LLC raised its stake in MacroGenics by 52.3% during the second quarter. Cresset Asset Management LLC now owns 26,720 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 9,172 shares during the period. 96.89% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

MGNX has been the topic of a number of analyst reports. B. Riley Financial raised shares of MacroGenics from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $3.00 to $9.00 in a research note on Friday, April 10th. Citigroup reaffirmed a “market perform” rating on shares of MacroGenics in a research note on Tuesday, February 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MacroGenics in a research note on Friday, May 8th. Wall Street Zen raised shares of MacroGenics from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Finally, Barclays lifted their target price on shares of MacroGenics from $4.00 to $6.00 and gave the stock an “overweight” rating in a research note on Monday, April 20th. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $5.50.

MacroGenics Stock Performance

MacroGenics stock opened at $4.47 on Wednesday. The company’s 50 day simple moving average is $3.39 and its 200-day simple moving average is $2.31. The company has a market capitalization of $284.11 million, a price-to-earnings ratio of -4.06 and a beta of 1.08. MacroGenics, Inc. has a 1 year low of $1.18 and a 1 year high of $4.64.

MacroGenics (NASDAQ:MGNX) last released its quarterly earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.01). The company had revenue of $20.78 million during the quarter, compared to analysts’ expectations of $15.24 million. MacroGenics had a negative net margin of 44.79% and a negative return on equity of 147.80%. Equities analysts expect that MacroGenics, Inc. will post -1.58 earnings per share for the current year.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody–based therapeutics for the treatment of cancer and autoimmune diseases. The company leverages proprietary Fc engineering technologies to enhance immune engagement and extend the activity of its antibodies. Since its founding in 2000, MacroGenics has advanced several product candidates through clinical trials, most notably margetuximab, a HER2-targeted antibody designed to improve outcomes in patients with HER2-positive breast cancer.

Central to MacroGenics’ research platform are its ADAPTIR and Trident bispecific antibody technologies.